Blocking and releasing these checkpoints in a susceptible, older population may provoke GCA, a theory supported by the role of abatacept, a novel treatment for GCA that contains CTLA-4 and inhibits CD28-mediated T cell co-stimulation [124]. The gene discussed is CD28; the disease is temporal arteritis.